CAP7.1(一种新型依托泊苷前药)在难治性实体瘤成人患者中的首次人体剂量递增与药代动力学研究
这项开放标签的I期剂量递增试验在多种实体癌成人患者中确定CAP7.1的最大耐受剂量(MTD)、安全性、药代动力学和抗肿瘤活性。19例患者分入45、90、150和200 mg/m2/day四个剂量组,MTD为200 mg/m2,耐受性良好,仅最高两个剂量组出现血液学毒性(3例剂量限制性毒性),观察到1例部分缓解和11例疾病稳定。
要点
- CAP7.1在难治性实体瘤成人中MTD为200 mg/m2/day。
- 仅最高两个剂量组出现血液学毒性,包括3例剂量限制性毒性(2例发热性中性粒细胞减少和1例脓毒症),经适当治疗可逆。
- 观察到1例部分缓解和11例疾病稳定,作为疗效的支持性证据。
核心结论
- CAP7.1的MTD为200 mg/m2。
- CAP7.1在难治性肿瘤中具有良好的安全性特征和初步抗肿瘤疗效,值得在临床研究中进一步评估。
研究设计与样本
- 开放标签的I期剂量递增试验,在成人多种实体癌患者中开展。
- 符合条件的高级、难治性实体恶性肿瘤成人患者接受CAP7.1静脉输注,连续5天。
- 剂量在四个队列中递增,每个队列3至6例患者,起始剂量为45 mg/m2/day。
- 在无疾病进展和不可耐受毒性情况下,治疗周期以21天间隔重复。
- 评估安全性、药代动力学和疗效,并确定MTD和剂量限制性毒性(DLT)。
主要发现
- 19例患者被分配至四个CAP7.1剂量队列(45、90、150和200 mg/m2/day)。
- CAP7.1耐受性良好。
- 在最高两个剂量水平观察到血液学毒性,仅包括3例DLT(2例发热性中性粒细胞减少和1例脓毒症),经适当治疗可逆。
- 未观察到器官毒性。
- 非血液学毒性(轻至中度)主要包括恶心、乏力、呕吐、发热和脱发。
关键数值与推荐
- MTD为200 mg/m2。
- 剂量限制性毒性共3例:2例发热性中性粒细胞减少和1例脓毒症,仅见于最高两个剂量水平。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出CAP7.1在难治性肿瘤中的初步抗肿瘤疗效值得在临床研究中进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: An open-label, phase I dose-escalation trial was performed in adult patients with various solid cancers to identify the maximum tolerated dose (MTD), to assess the safety, pharmacokinetic profile and anti-tumour activity of the new prodrug CAP7.1. The prodrug is converted to its active moiety etoposide via carboxylesterases in selective cells leading to a better tolerability and higher efficacy in therapeutic resistance cells and children with refractory neuroblastoma. PATIENTS AND METHODS: Eligible adult patients with advanced, refractory, solid malignancies received CAP7.1 as intravenous infusion on 5 consecutive days. Doses were escalated in four cohorts consisting of three to six patients, with a starting dose of 45 mg/m2/day. Treatment cycles were repeated in 21-day intervals in the absence of disease progression and prohibitive toxicity. The safety, pharmacokinetics and efficacy were evaluated, and the MTD and dose-limiting toxicity (DLT) were determined. RESULTS: Nineteen patients were assigned to four CAP7.1 dose cohorts (45, 90, 150 and 200 mg/m2/day). CAP7.1 was well tolerated. Haematotoxicity was observed at the two highest dose levels including three DLTs (two febrile neutropenia and one sepsis) only and were reversible with adequate therapy. No organ toxicity was observed. Non-haematological toxicities (mild-moderate) consist mainly of nausea, fatigue, vomiting, pyrexia and alopecia. One partial response and 11 stable diseases were observed as supporting signs of efficacy. CONCLUSION: MTD of CAP7.1 was reached at the dose of 200 mg/m2. A favourable safety profile and initial anti-tumour efficacy of CAP7.1 in therapeutic refractory tumours warrant further evaluation in clinical studies.
引用
- Keilholz U, Rohde L, Mehlitz P, et al. First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours. Eur J Cancer. 2017. PMID: 28531881. doi:10.1016/j.ejca.2017.03.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。